Compare JetBlue Airways Corporation (JBLU) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JetBlue Airways Corporation vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? JetBlue Airways Corporation trades at $3.03 (market cap $1.26B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: JetBlue Airways Corporation is the larger of the two by market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, JetBlue Airways Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold JetBlue Airways Corporation for 44 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| JBLU | MRVI | |
|---|---|---|
Market Cap | $1.26B | $972.90M |
Volume | 40,642,525 | 4,325,710 |
Sector | Industrials | Health |
52-Week High | $6.46 | $9.00 |
52-Week Low | $3.01 | $2.83 |
Typical Hold Time | 44 Days | 0 Days |
Enterprise Value | $8.63B | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JetBlue (JBLU) trades at $3.01, down 16.85% in the last 24 hours, reflecting significant bearish pressure. The stock exhibits weak fundamentals with a negative net income margin of -9.32% and consecutive quarterly losses, though it beat EPS expectations in Q2 2026. Technical indicators are predominantly bearish, with the stock trading near key support levels. Recent news highlights expansion efforts like new routes to Colombia and the launch of BlueFirst premium seating, aiming to boost revenue amid industry challenges.
The outlook remains challenging due to persistent losses, high debt levels, and elevated fuel costs. While analyst consensus suggests a hold rating with a $5.89 price target implying potential upside, risks from competitive pressures and macroeconomic factors dominate. Investment appeal is limited to speculative positions betting on a operational turnaround despite current headwinds.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
